ClinicalTrials.gg
CompletedNCT06911320Updated Jul 31, 2026

Study of Bemnifosbuvir/Ruzasvir as a Fixed-dose Combination in Subjects With Normal or Severely Impaired Renal or Hepatic Function

A Phase 1 interventional study of Bemnifosbuvir (BEM)/Ruzasvir (RZR) as a fixed-dose combination in Healthy Volunteer Study, Hepatic Impairment and Renal Impairment, sponsored by Atea Pharmaceuticals, Inc.. Completed at 2 sites in United States. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-31.

Sponsored by Atea Pharmaceuticals, Inc. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
28
Allocation
Non-randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 553 studies in Renal Insufficiency with a site in United States — 40 open to participants now, 57 under way, 3 of them phase 3. Renal Insufficiency · United States.

Enrollment
267th of 468
28 · median 32
Started
2025
with 21 others
Phase 1
232 of 553
14 open now
Registered
524th of 553
by date

Among the 553 studies in Renal Insufficiency with a site in United States, this one is the 267th largest by enrollment of the 468 interventional ones that give a count, is one of 22 that started in 2025, is one of 232 in phase 1, and was the 524th registered.

Renal Insufficiency

1,413 studies on the registry are indexed under Renal Insufficiency; 146 are open to participants now.

Browse Renal Insufficiency studies →

Open to participants now

40 of the 553 studies in Renal Insufficiency with a site in United States are open now. Recruiting first, the newest first:

35 more — sign in →

All 40 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 92 Renal Insufficiency studies recruiting now, 48 (52%) set no upper age limit and 19 (21%) stop at 75 or younger; 8 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 553 studies in Renal Insufficiency with a site in United States, or all of them as a file.
02

Study summary

To Assess the Effect of Severe Hepatic or Renal Impairment on the Pharmacokinetics of Bemnifosbuvir/Ruzasvir After a Single Dose

03

Conditions studied

  • Healthy Volunteer Study
  • Hepatic Impairment
  • Renal Impairment

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must agree to use two methods of from Screening through 90 days after administration of the last dose of study drug
  • Females must have a negative pregnancy test at Screening and prior to dosing
  • of 18.5 to 43.0 kg/m2
  • Willing to comply with the study requirements and to provide written

Renal Impaired Subjects (Group 1):

  • Considered stable in the judgement of an Investigator
  • Presence of severe renal impairment or kidney failure (as defined by \< 30 mL/ min)

Hepatic Impaired Subjects (Group 2):

  • Considered stable for at least 1 month prior to Screening, as per the judgement of an Investigator
  • Presence of severe hepatic impairment ( Class C: score of 10 to 15).

Subjects with Normal Hepatic and Renal Function (Group 3):

  • Medically healthy, in the opinion of an Investigator
  • Must match by gender, age (± 10 years), and BMI (within 20%) to the pooled mean values of subjects with severe renal and hepatic impairment

Exclusion criteria

Exclusion Criteria:

  • Pregnant or breastfeeding
  • Infected with virus, virus or
  • Abuse of alcohol or drugs
  • Use of other drugs within 28 days of dosing
  • Other medical conditions or laboratory abnormalities

Renal and Hepatic Impaired Subjects (Group 1 and 2):

  • Presence of poorly controlled Type 1 or Type 2 diabetes as defined by > 10%
  • Undergoing any method of dialysis
  • Subjects requiring treatment for hepatic impairment or other chronic disease must be on a stable treatment plan

Renal Impaired Subjects (Group 1):

  • History of renal transplant
  • Concurrent use of medications known to affect the elimination of serum creatinine

Hepatic Impaired Subjects (Group 2):

  • History of liver transplant
  • Evidence of hepatic carcinoma presence at Screening
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
28 participants (actual)

Study arms

  • Experimental
    Group 1 - Severe Renal Impairment

    Single dose Bemnifosbuvir (BEM)/Ruzasvir (RZR) as a fixed-dose combination

    Drug: Bemnifosbuvir (BEM)/Ruzasvir (RZR) as a fixed-dose combination

  • Experimental
    Group 2 - Severe Hepatic Impairment

    Single dose Bemnifosbuvir (BEM)/Ruzasvir (RZR) as a fixed-dose combination

    Drug: Bemnifosbuvir (BEM)/Ruzasvir (RZR) as a fixed-dose combination

  • Experimental
    Group 3 - Matched Healthy Subjects

    Single dose Bemnifosbuvir (BEM)/Ruzasvir (RZR) as a fixed-dose combination

    Drug: Bemnifosbuvir (BEM)/Ruzasvir (RZR) as a fixed-dose combination

Interventions

  • DrugBemnifosbuvir (BEM)/Ruzasvir (RZR) as a fixed-dose combination

    A single dose of BEM/RZR will be administered

    Also known as: AT-527 (BEM) and AT-038 (RZR)

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics (PK) of BEM/RZR Maximum plasma concentration (Cmax)

    Time frame: Day 1

  2. Pharmacokinetics (PK) of BEM/RZR Area under the plasma concentration-time curve (AUC)

    Time frame: Day 1

  3. Pharmacokinetics (PK) of BEM/RZR AUC

    Time frame: Day 1

07

Study locations

2 sites
  • Atea Study Site
    Orlando, Florida 32809, United States
  • Atea Study Site
    Tampa, Florida 33603, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2025 to primary completion in Apr 2026, 12 months.

Of 213 industry-sponsored phase 1 interventional studies under Renal Insufficiency, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's 12 months is above that.

Counting every sponsor, half of 231 studies reached it within 8 months; a quarter within 5 and three quarters within 16.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 24, 2025
First posted
Apr 4, 2025
StartActual
Apr 9, 2025
Primary completionActual
Apr 30, 2026
CompletionActual
Apr 30, 2026
Last update
Jul 31, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 31, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06911320
Responsible party
Sponsor
First posted
Apr 4, 2025
Start date
Apr 9, 2025
Primary completion
Apr 30, 2026
Completion
Apr 30, 2026
Last update
Jul 31, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion